Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

NCT02226172 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Glasdegib (PF-04449913)
DRUG: Placebo

Sponsor

Pfizer